Final Development Stage For Prolia Reflects Amgen's Eye On Advertising
Executive Summary
Amgen's latest round of studies for the osteoporosis drug Prolia (denosumab) reflects the closing stage of the development program and shows how the company is laying groundwork for an advertising campaign - or at least a convincing argument for insurance coverage